<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fertility, pregnancy, and nursing in inflammatory bowel disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fertility, pregnancy, and nursing in inflammatory bowel disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Fertility, pregnancy, and nursing in inflammatory bowel disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark A Peppercorn, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Uma Mahadevan, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sunanda V Kane, MD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Inflammatory bowel disease (IBD) can affect patients in their childbearing years and therefore has implications on fertility, pregnancy, and nursing.</p><p>This topic will review issues related to fertility in patients with IBD and the diagnosis and management of IBD in pregnant and nursing patients. The medical management of IBD in the general population is discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">"Management of the hospitalized adult patient with severe ulcerative colitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.)</p><p></p><p>Our approach is consistent with a multidisciplinary guide to preconception counseling and caring for pregnant patients with IBD [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H692771488"><span class="h1">FERTILITY</span><span class="headingEndMark"> — </span>Patients with quiescent IBD do not have decreased fertility as compared with the age-matched general population [<a href="#rid2">2-6</a>]. Low birth rates among patients with IBD are often due to patient choice rather than disease-related infertility [<a href="#rid2">2,5</a>]. (See  <a class="medical medical_review" href="/z/d/html/7396.html" rel="external">"Overview of infertility"</a>.)</p><p>However, IBD can cause infertility in the following circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>Active inflammation in patients with Crohn disease may result in infertility due to inflammation involving the fallopian tubes and ovaries [<a href="#rid6">6</a>]. Perianal disease can also cause dyspareunia. (See  <a class="medical medical_review" href="/z/d/html/5408.html" rel="external">"Female infertility: Causes", section on 'Fallopian tube abnormalities/pelvic adhesions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medications may decrease fertility in male patients. As examples, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> can cause reversible oligospermia. In addition, sulfasalazine is associated with reduced sperm motility and abnormal sperm morphology [<a href="#rid7">7-10</a>].</p><p></p><p class="bulletIndent1">However, studies suggest that anti-tumor necrosis factor (anti-TNF) therapy does not impair sperm quality [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgery may impact fertility in patients with IBD. Proctocolectomy in males may lead to impotence or ejaculatory difficulties [<a href="#rid12">12</a>]. Restorative proctocolectomy with ileoanal anastomosis has been associated with dyspareunia and a reduction in fertility due to scarring and formation of adnexal adhesions [<a href="#rid3">3,13,14</a>]. (See  <a class="medical medical_review" href="/z/d/html/86198.html" rel="external">"Surgical management of Crohn disease", section on 'Surgical approaches'</a> and  <a class="medical medical_review" href="/z/d/html/1375.html" rel="external">"Surgical management of ulcerative colitis", section on 'Surgical options'</a>.)</p><p></p><p class="bulletIndent1">Female IBD patients with infertility may seek assisted reproductive technology (ART) treatment. A cohort study based on Danish health registries evaluated the chance of live birth in patients with IBD who underwent ART treatments [<a href="#rid15">15</a>]. Patients with ulcerative colitis had lower rates of successful pregnancy compared with patients without IBD (odds ratio [OR] 0.73, 95% CI 0.58-0.92). Patients who had surgery for Crohn disease were also less likely to have live birth following ART (adjusted OR 0.51, 95% CI 0.29-0.91).</p><p></p><p class="headingAnchor" id="H692770159"><span class="h1">PRECONCEPTION COUNSELING</span><span class="headingEndMark"> — </span>Preconception counseling offers an opportunity for the clinician to address specific patient concerns regarding the risk of transmission of IBD or other diseases to their offspring, to optimize control of disease activity and nutritional status, avoid inappropriate medication cessation, and discontinue medications that may adversely affect pregnancy. (See  <a class="medical medical_review" href="/z/d/html/448.html" rel="external">"The preconception office visit"</a>.)</p><p></p><p class="headingAnchor" id="H692770651"><span class="h2">IBD risk in offspring</span><span class="headingEndMark"> — </span>Although IBD follows a non-Mendelian pattern of inheritance, genetically determined factors contribute to IBD susceptibility. First-degree relatives of patients with IBD are approximately 3 to 20 times more likely to develop IBD as compared with the general population [<a href="#rid16">16-19</a>]. In a large national, registry-based cohort study with a median follow-up of 10 years, the risk of developing IBD was increased in offspring born to mothers with ulcerative colitis (HR 4.6, 95% CI 3.5-6.2) and mothers with Crohn disease (HR 7.7, 95% CI 5.7-10.5) compared with mothers without IBD; the impact of paternal IBD was not evaluated [<a href="#rid20">20</a>].</p><p>Clinical features of the disease also demonstrate a heritable pattern with concordance in disease location (eg, ileal versus colonic Crohn disease) and type (eg, fibrostenotic Crohn disease, fistulas) [<a href="#rid21">21-26</a>]. Subsequent generations may demonstrate "genetic anticipation" with the development of earlier onset of IBD and more severe disease as compared with their parents [<a href="#rid19">19,27</a>].</p><p>The role of genetic factors that increase susceptibility to IBD and genetic syndromes associated with IBD is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4062.html" rel="external">"Genetic factors in inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H521044030"><span class="h2">Disease control</span><span class="headingEndMark"> — </span>Female patients with IBD should attempt conception at a time when the disease is in remission. Patients who have active disease at conception are more likely to have active disease during pregnancy [<a href="#rid28">28</a>]. Data have suggested that patients with ulcerative colitis are more likely to have disease activity during pregnancy than patients with Crohn disease [<a href="#rid29">29</a>]. This may reflect the cytokine production of the placenta and its impact on ulcerative colitis. Having active disease is associated with a significant increase in the rate of preterm birth [<a href="#rid30">30</a>]. The risk of disease activity in the untreated patient should be discussed alongside the potential risk of any medications used during pregnancy to maintain remission. (See  <a class="medical medical_review" href="/z/d/html/4966.html" rel="external">"Preterm birth: Definitions of prematurity, epidemiology, and risk factors for infant mortality"</a>.)</p><p class="headingAnchor" id="H692771764"><span class="h2">Medications</span><span class="headingEndMark"> — </span>Medications that may affect fertility or adversely affect pregnancy should be discontinued, when possible, for patients planning pregnancy. The risks and benefits of fetal drug exposure versus discontinuation of medications and its attendant risk of flare should be specifically discussed. These risks and benefits are discussed in detail below. (See <a class="local">'Medications during pregnancy and lactation'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Nonimmunosuppressive agents – <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a> causes reversible oligospermia that resolves within discontinuation of therapy. Oligospermia is not associated with 5-aminosalicylic acid (5-ASA) medications (eg, <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a>). Male patients on sulfasalazine should therefore be transitioned to 5-ASAs four months prior to conception  (<a class="graphic graphic_table graphicRef86818" href="/z/d/graphic/86818.html" rel="external">table 1</a>) [<a href="#rid31">31,32</a>]. (See <a class="local">'Sulfasalazine and 5-aminosalicylic acid'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppressive agents – In female patients, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> is contraindicated because it is an abortifacient and potent teratogen. Methotrexate is associated with oligospermia but has not been associated with adverse fetal outcomes related to paternal exposure [<a href="#rid33">33-35</a>]. Because of the risk of oligospermia, male patients should discontinue methotrexate and use contraception for at least four months prior to conception. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Methotrexate'</a> and <a class="local">'Medications during pregnancy and lactation'</a> below.)</p><p></p><p class="bulletIndent1">Data on paternal exposure to immunomodulators and/or biologic agents around the time of conception have suggested that such agents were not associated with increased risk of adverse birth outcomes [<a href="#rid36">36-38</a>]. In a database study including 7453 males with immune-mediated inflammatory diseases (eg, inflammatory bowel disease, psoriasis/psoriatic arthritis) whose partners had conceived, exposure to thiopurines (relative risk [RR], 1.12; 95% CI 0.66-1.76), <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (RR, 0.67; 95% CI 0.21-1.55), anti-tumor necrosis factor (anti-TNF) agents (RR, 1.14; 95% CI 0.81-1.57), or non-TNF targeting biologic agents (eg, <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">vedolizumab</a>, <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>) (RR, 1.75; 95% CI 0.80-3.24) was not associated with increased risk of major congenital anomalies, preterm birth or low birth weight [<a href="#rid37">37</a>]. In a prior meta-analysis, periconception exposure to thiopurines in male patients was not associated with congenital anomalies [<a href="#rid36">36</a>]. These findings lend support for the safety of these biologics and immunomodulators at the time of conception for male patients.</p><p></p><p class="bulletIndent1">We do not routinely recommend that male patients on thiopurines discontinue treatment unless the couple has a history of infertility or miscarriages that is otherwise unexplained. In such cases, if analysis of male factor infertility suggests abnormal semen quality, and no other factor is identified, a trial of thiopurine discontinuation can be considered. (See <a class="local">'Azathioprine and mercaptopurine'</a> below and  <a class="medical medical_review" href="/z/d/html/7473.html" rel="external">"Causes of male infertility"</a>.)</p><p></p><p class="bulletIndent1">Data on the effect of thiopurines on female fertility are lacking.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> does not appear to reduce male fertility or to have a demonstrable effect on sperm [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Cyclosporine'</a> and <a class="local">'Cyclosporine'</a> below.)</p><p></p><p class="headingAnchor" id="H805110346"><span class="h2">Nutrition and supplements</span><span class="headingEndMark"> — </span>Consultation with a nutritionist should be considered to offer advice on eating a well-balanced, healthy diet. We obtain nutrition consultation for patients with risk factors for reduced gestational weight gain such as those with active disease and surgical changes impacting absorption. [<a href="#rid40">40</a>]. <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">Folic acid</a> is important for neural tube development during pregnancy. Folate supplementation (2 mg daily) should be recommended in patients with IBD on low residue diets, with ileal involvement, and patients on medications that interfere with folic acid metabolism (eg, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>) [<a href="#rid6">6,41</a>]. (See  <a class="medical medical_review" href="/z/d/html/423.html" rel="external">"Preconception and prenatal folic acid supplementation"</a>.)</p><p>Patients with IBD are at risk for iron and vitamin B12 deficiency. Furthermore, iron requirements increase during pregnancy. Iron and B12 levels should therefore be checked in the first trimester and supplementation should be provided as needed. (See  <a class="medical medical_review" href="/z/d/html/5887.html" rel="external">"Vitamin and mineral deficiencies in inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/z/d/html/453.html" rel="external">"Nutrition in pregnancy: Dietary requirements and supplements"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">PREGNANCY AND LACTATION</span><span class="headingEndMark"> — </span>Patients with IBD are at an increased risk for worse obstetric and medical outcomes compared with the age-matched general population [<a href="#rid42">42-44</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Effect of pregnancy on IBD</span><span class="headingEndMark"> — </span>For patients with quiescent IBD at conception, the course of IBD is approximately the same as in nonpregnant patients [<a href="#rid45">45</a>]. Patients with Crohn disease have a similar disease course during pregnancy and the postpartum as nonpregnant patients with IBD. However, for patients with ulcerative colitis, there is an increased risk of disease flare compared with a patient with Crohn disease. The reason for this is unclear and may be associated with smoking cessation, cytokines secreted by the placenta or undertreatment of ulcerative colitis patients prior to pregnancy [<a href="#rid29">29</a>].</p><p>Approximately one-third of patients with quiescent disease at conception relapse during the pregnancy, similar to the general IBD population [<a href="#rid46">46</a>]. Relapses are more common during the first trimester. However, remission achieved during pregnancy is likely to be sustained throughout the remainder of the pregnancy.</p><p>In contrast, approximately 70 percent of patients with active disease at conception are likely to have continued or worsening symptoms during pregnancy [<a href="#rid47">47,48</a>]. (See  <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults", section on 'Acute complications'</a>.)</p><p>The events occurring during one pregnancy do not correlate with the course in subsequent pregnancies [<a href="#rid49">49</a>]. However, pregnancy may be protective in the long term, as suggested by lower relapse rates up to ten years following pregnancy compared with rates prior to pregnancy [<a href="#rid50">50,51</a>]. As parity increases, the risk for surgery to treat IBD also decreases, though this may simply be because healthier patients are more likely to have multiple pregnancies [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Effect of IBD on pregnancy</span><span class="headingEndMark"> — </span>Pregnant patients with IBD may be at increased risk for antepartum hemorrhage, low birth weight infants, and premature delivery [<a href="#rid42">42,44,52-55</a>]. However, the risk of congenital abnormalities does not appear to be increased [<a href="#rid42">42,56,57</a>].</p><p>The degree of disease activity may account, in part, for the poor pregnancy-related outcomes [<a href="#rid56">56,58</a>]. The risk of poor pregnancy outcomes in patients with IBD is greatest in those who have active disease at the time of conception, and in whom remission may be difficult to achieve during pregnancy [<a href="#rid4">4,56,58-62</a>]. As an example, in a Danish cohort study, the risk of preterm birth increased if the mother was hospitalized during pregnancy (odds ratio [OR] 1.4), and if the first hospitalization for ulcerative colitis occurred during pregnancy (OR 3.4) [<a href="#rid56">56</a>].</p><p>Patients with IBD should be followed as high-risk obstetric patients, particularly in the third trimester, and if the disease is active. (See  <a class="medical medical_review" href="/z/d/html/457.html" rel="external">"Overview of antepartum fetal assessment"</a> and  <a class="medical medical_review" href="/z/d/html/6761.html" rel="external">"Spontaneous preterm birth: Overview of risk factors and prognosis", section on 'Chronic medical disorders'</a>.)</p><p class="headingAnchor" id="H805115129"><span class="h2">Effect of lactation on IBD</span><span class="headingEndMark"> — </span>Breastfeeding does not independently affect the course of disease in IBD after adjusting for an increase in disease activity due to cessation of IBD medications. However, data suggest that over 50 percent of female patients with IBD do not breastfeed their children either because of a clinician recommendation, fear of medication interactions, or personal choice [<a href="#rid63">63</a>]. It is therefore important to discuss the benefits of breastfeeding as well as the compatibility of several anti-inflammatory and immunosuppressive medications with breastfeeding as discussed below. (See  <a class="medical medical_review" href="/z/d/html/5013.html" rel="external">"Infant benefits of breastfeeding"</a> and <a class="local">'Medications during pregnancy and lactation'</a> below and  <a class="medical medical_review" href="/z/d/html/4978.html" rel="external">"Breastfeeding: Parental education and support"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">EVALUATING DISEASE ACTIVITY DURING PREGNANCY AND LACTATION</span></p><p class="headingAnchor" id="H4118002760"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>Fecal calprotectin is a stool marker of intestinal inflammation that can be measured in pregnant patients to assess disease activity [<a href="#rid64">64-68</a>]. In a cohort study including 85 pregnant patients with IBD, a fecal calprotectin level ≥250 mcg/g during the second trimester was associated with higher rates of low birth weight (35 versus 4 percent) [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Stool studies'</a>.)</p><p class="headingAnchor" id="H3696093018"><span class="h2">Endoscopy and imaging studies</span><span class="headingEndMark"> — </span>Endoscopy or imaging studies may be indicated during pregnancy for the diagnosis of suspected IBD or for the assessment of disease severity, or diagnosis and management of complications in patients with established IBD. However, it is important to consider the risks, benefits, and optimal timing of such a diagnostic evaluation in pregnant or nursing patients. (See  <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">"Management of the hospitalized adult patient with severe ulcerative colitis", section on 'Pretreatment evaluation'</a>.)</p><p>The safety and efficacy of endoscopic procedures during pregnancy have not been extensively studied. Endoscopy should be performed during pregnancy only if there is a strong indication (eg, significant bleeding) or if the information is critical for making treatment decisions (eg, establish the diagnosis of IBD in a pregnant patient with chronic diarrhea or stage disease if new therapies are needed). Flexible sigmoidoscopy, which can be performed without sedation or colonic preparation, is low risk in pregnancy in any trimester [<a href="#rid69">69</a>]. While there are several reports of colonoscopies being performed during pregnancy without complications, experience is relatively limited compared with sigmoidoscopy [<a href="#rid69">69,70</a>]. Obstetrical staff should be closely involved and the degree of maternal and fetal monitoring should be individualized. Recommendations for procedural sedation for endoscopy in pregnant and nursing patients are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2567.html" rel="external">"Gastrointestinal endoscopy in adults: Procedural sedation administered by endoscopists", section on 'Special populations'</a>.)</p><p>Radiographic studies involving ionizing radiation (eg, computed tomography enterography, abdominal radiographs, small bowel follow-through) should be avoided in pregnancy if possible. These studies can be performed if they are necessary for maternal management and if there is no alternative imaging modality available. Several techniques can be used to minimize fetal radiation exposure. Magnetic resonance (MR) enterography is the preferred diagnostic modality in the absence of institutional expertise with ultrasound for IBD because it avoids the ionizing radiation of computed tomography. While MR enterography can be done in any trimester, intravenous gadolinium crosses the placenta [<a href="#rid71">71</a>]. The theoretical risk to the patient needs to be weighed against the additional imaging benefit of using gadolinium. However, oral contrast is routinely used. Intestinal ultrasound, where available, is an accurate and low risk mode of assessing disease activity in pregnancy, at least until late in the third trimester [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a>.)</p><p class="headingAnchor" id="H81259234"><span class="h1">MEDICATIONS DURING PREGNANCY AND LACTATION</span><span class="headingEndMark"> — </span>The choice of anti-inflammatory and immunosuppressive use during pregnancy and lactation should be based upon their relative safety and indications as well as the risk of relapse of IBD if the medications are discontinued.</p><p>Active IBD itself is associated with poor pregnancy outcomes, and therefore the risks associated with discontinuing some medications (eg, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, anti-tumor necrosis factor [anti-TNF] agents) are higher than the known risks of the medications themselves. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p>The recommendations on lactation are consistent with <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK501922%2F%3Freport%3Dclassic&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trxbRM9n9k9jxarxPZM5TS5htB9tQgQ%2BhkEZ6u8L6V76cKfsHR1IKbAngeDe8Jfsj0k%3D&amp;TOPIC_ID=4083" target="_blank">the Drugs and Lactation Database of the US National Library of Medicine</a> (LactMed) unless noted otherwise. LactMed is a free, online resource for information on maternal and infant levels of drugs, possible effects on breastfed infants and on lactation.</p><p class="headingAnchor" id="H1154029918"><span class="h2">Aspirin</span><span class="headingEndMark"> — </span>Low dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (81 to 162 mg) given from week 12 to 16 of gestation onward, has been shown to reduce the risk of preeclampsia in patients at risk [<a href="#rid73">73,74</a>]. Pregnant patients with IBD are at higher risk for preeclampsia, and strategies to prevent preeclampsia including pharmacologic prophylaxis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6817.html" rel="external">"Preeclampsia: Prevention"</a>.)</p><p class="headingAnchor" id="H851223639"><span class="h2">Antibiotics</span><span class="headingEndMark"> — </span>Antibiotics, <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> and <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, are frequently used in the management of patients with inflammatory bowel disease. (See  <a class="medical medical_review" href="/z/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults", section on 'Antibiotics'</a> and  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'The acutely ill patient with Crohn disease'</a>.)</p><p>The use of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> should be limited to short courses. A number of studies have suggested that metronidazole is not associated with an increased risk of congenital anomaly or cancer [<a href="#rid75">75,76</a>]. However, long-term use in pregnancy remains controversial because it is carcinogenic in rodents and mutagenic in bacteria [<a href="#rid77">77,78</a>]. In a study of 922 patients exposed to metronidazole in pregnancy, there was no association with congenital anomalies, preterm birth, or low birth weight [<a href="#rid79">79</a>].</p><p><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is excreted into breast milk and is a possible mutagen. Breastfeeding should be avoided for 12 to 24 hours after a single oral dose. [<a href="#rid80">80</a>]. <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">Ciprofloxacin</a> is not recommended in pregnant patients and in children under age 18 as it affects growing cartilage and can cause arthropathy. However, among 200 pregnancies exposed to fluoroquinolones (including ciprofloxacin), the incidence of adverse events were similar to controls [<a href="#rid81">81</a>].</p><p><a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">Ciprofloxacin</a> is excreted into breast milk, but short courses of ciprofloxacin are probably safe during breastfeeding due to the low concentration in breast milk [<a href="#rid80">80</a>].</p><p>Amoxicillin-clavulanic acid has a favorable safety profile and is considered acceptable for use during pregnancy and lactation [<a href="#rid82">82</a>]. <a class="drug drug_general" data-topicid="10202" href="/z/d/drug information/10202.html" rel="external">Rifaximin</a> has no published safety data in human pregnancy or lactation. Per their label, animal studies have revealed evidence of teratogenicity at doses about 0.9 to 5 times (rats) and 0.7 to 33 times (rabbits) the recommended human doses of 600 to 1650 mg per day [<a href="#rid83">83</a>]. It should be avoided in pregnancy. There are no published pregnancy safety data for probiotics in IBD. However, there are several large ongoing trials regarding the use of specific probiotics in all pregnancies to improve outcomes including preterm birth and infant infections and allergies [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H2184318683"><span class="h2">Sulfasalazine and 5-aminosalicylic acid</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a> and 5-aminosalicylic acid (5-ASA) drugs can be used during pregnancy and lactation.</p><p>The incidence of decreased birth weight, prematurity, spontaneous abortion, stillbirths, or congenital anomaly is similar in children born to mothers taking <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> compared with the general population [<a href="#rid85">85</a>]. Sulfasalazine and its sulfapyridine metabolite can be found in umbilical cord blood at similar concentrations to maternal blood. However, these concentrations do <strong>not</strong> cause significant displacement of bilirubin from albumin [<a href="#rid86">86,87</a>]. As a result, sulfasalazine does not have to be discontinued during pregnancy.</p><p>Folate supplementation (2 mg daily) should be recommended in patients on <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> as it interferes with <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> metabolism [<a href="#rid6">6</a>]. (See <a class="local">'Nutrition and supplements'</a> above.)</p><p>Studies suggest that 5-ASA agents by themselves are safe during pregnancy [<a href="#rid88">88-91</a>]. Enteric coating of <a class="drug drug_general" data-topicid="9614" href="/z/d/drug information/9614.html" rel="external">mesalamine</a> with dibutyl phthalate (DBP) has been associated with skeletal malformations and adverse effects on the male reproductive system in fetal animal models exposed to high doses of DBP [<a href="#rid92">92</a>]<em>.</em> However, at this time there is no commercial preparation with DBP in the coating  (<a class="graphic graphic_table graphicRef86818" href="/z/d/graphic/86818.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/z/d/html/111468.html" rel="external">"Occupational and environmental risks to reproduction in females: Specific exposures and impact", section on 'Bisphenol A and other phenols'</a>.)</p><p><a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a> and 5-ASAs are excreted in breast milk in low concentrations. Infants whose mothers are on sulfasalazine and 5-ASAs should be monitored for the development of diarrhea, a rare complication of breastfeeding [<a href="#rid80">80,93,94</a>].</p><p class="headingAnchor" id="H140248856"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids are considered low risk in pregnancy and should be administered for the same indications as a nonpregnant patient with IBD. The lowest possible dose of systemic glucocorticoids should be used and they should not be considered an alternative to standard maintenance therapy. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Glucocorticoids'</a> and  <a class="medical medical_review" href="/z/d/html/6761.html" rel="external">"Spontaneous preterm birth: Overview of risk factors and prognosis"</a>.)</p><p>Although older studies have demonstrated a threefold increase in the risk of cleft palate after maternal exposure to glucocorticoids, the absolute risk is low (0.2 to 0.4 percent) [<a href="#rid95">95</a>] and multiple other studies have not confirmed that risk [<a href="#rid96">96</a>]. In addition, as palatal closure is usually complete by the 12<sup>th</sup> week of pregnancy, the risk is limited to administration during the first trimester. (See  <a class="medical medical_review" href="/z/d/html/6769.html" rel="external">"Etiology, prenatal diagnosis, obstetric management, and recurrence of cleft lip and/or palate"</a>.)</p><p>Fetal adrenal insufficiency and low birth weight have also been associated with glucocorticoids [<a href="#rid97">97</a>]. However, adrenal insufficiency of the fetus following maternal administration of glucocorticoids is rare as rapid maternal metabolism of <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a>, binding to serum proteins, and conversion to inactive metabolites by placental 11 beta-hydroxysteroid dehydrogenase results in relatively low fetal concentrations [<a href="#rid98">98,99</a>]. However, long-term administration of high doses of glucocorticoids (&gt;20 mg) is associated with adrenal insufficiency and warrants close neonatal monitoring. (See  <a class="medical medical_review" href="/z/d/html/457.html" rel="external">"Overview of antepartum fetal assessment"</a>.)</p><p>Glucocorticoids have the potential for exacerbating pregnancy-induced hypertension, gestational diabetes, and preterm delivery from premature rupture of membranes [<a href="#rid100">100</a>]. Therefore, pregnant patients on glucocorticoids should be appropriately monitored for these complications [<a href="#rid95">95,101</a>]. (See  <a class="medical medical_review" href="/z/d/html/6805.html" rel="external">"Gestational hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/6790.html" rel="external">"Gestational diabetes mellitus: Glucose management and maternal prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/4800.html" rel="external">"Gestational diabetes mellitus: Obstetric issues and management"</a> and  <a class="medical medical_review" href="/z/d/html/6754.html" rel="external">"Preterm prelabor rupture of membranes: Clinical manifestations and diagnosis"</a>.)</p><p>Although low levels of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> and its metabolite, <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a>, can be measured in breast milk, these are unlikely to be clinically significant. In one study, following a dose of prednisolone 50 mg IV, an average of 0.025 percent was recovered from breast milk [<a href="#rid102">102</a>].</p><p class="headingAnchor" id="H3758623945"><span class="h2">Azathioprine and mercaptopurine</span><span class="headingEndMark"> — </span>Thiopurines, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">mercaptopurine</a>, should be continued during pregnancy if they are monotherapy [<a href="#rid103">103,104</a>]. In a meta-analysis of 3045 patients with IBD, thiopurine exposure was associated with preterm birth (odds ratio [OR] 1.7, 95% CI 1.3-2.2), but not with congenital abnormalities or low birth weight [<a href="#rid36">36</a>]. In addition, discontinuing azathioprine and mercaptopurine is associated with a high rate of relapse and active IBD is itself associated with an increased risk of low birth weight [<a href="#rid104">104-111</a>].</p><p><a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">Azathioprine</a> and <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">mercaptopurine</a> are detectable in breast milk but studies have demonstrated that levels in breast milk are low and metabolites are undetectable in breastfed neonates [<a href="#rid112">112,113</a>]. Although data are limited, these studies suggest that breastfeeding is safe. Breastfeeding can be continued while on azathioprine and mercaptopurine after a detailed discussion of the risks and benefits of breastfeeding [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Azathioprine and 6-mercaptopurine'</a>.)</p><p class="headingAnchor" id="H3266554519"><span class="h2">Cyclosporine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> is effective at inducing remission in patients with severe steroid refractory ulcerative colitis during pregnancy [<a href="#rid58">58</a>]. When the administration of cyclosporine is necessary during pregnancy, the minimum dose should be used. (See  <a class="medical medical_review" href="/z/d/html/4068.html" rel="external">"Management of the hospitalized adult patient with severe ulcerative colitis"</a>.)</p><p>In a meta-analysis, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> was not associated with an increase in risk of congenital malformations but was associated with increased rates of prematurity [<a href="#rid114">114</a>]. A higher incidence of small for gestational age infants has also been reported. However, it is unclear if fetal growth restriction and prematurity were due to cyclosporine or due to the mother’s underlying disease.</p><p><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> is excreted in breast milk, and therapeutic levels have been reported in breastfed infants [<a href="#rid115">115,116</a>]. However, as the amount of transfer is minimal, cyclosporine can be used in the breastfeeding mother and infant levels of drug can be monitored if concern for toxicity. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Cyclosporine'</a>.)</p><p class="headingAnchor" id="H2130501697"><span class="h2">Methotrexate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> is contraindicated in pregnancy as it is a potent abortifacient, and its use during pregnancy is associated with multiple skeletal abnormalities. Female patients who plan to conceive should, therefore, discontinue methotrexate and use contraception for at least three months, and ideally six months, prior to conception.</p><p>The rate of congenital malformations due to maternal <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> use is estimated to be 9 to 17 percent [<a href="#rid117">117,118</a>]. The risk of methotrexate-induced developmental toxicity is highest at 8 to 10 weeks of gestation and with doses ≥10 mg per week.</p><p>Breastfeeding is contraindicated in patients on <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> as it is excreted into breast milk and can accumulate in neonatal tissues [<a href="#rid6">6,119</a>]. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Methotrexate'</a>.)</p><p class="headingAnchor" id="H1607161760"><span class="h2">Anti-tumor necrosis factor agents</span><span class="headingEndMark"> — </span>Experience with anti-TNF agents used to treat IBD during pregnancy is reassuring [<a href="#rid120">120-125</a>]. The Toronto Consensus on Management of IBD in pregnancy recommended that pregnant patients on anti-TNF monotherapy for maintenance should continue therapy throughout pregnancy [<a href="#rid126">126</a>]. Switching from a combination of a biologic plus thiopurine therapy to anti-TNF monotherapy may be considered in very select low-risk patients. Low-risk patients are those in sustained remission prior to pregnancy (ie, symptomatic, glucocorticoid-free remission with endoscopic healing for at least three months duration) and no history of multiple medication failures, significant perianal disease, or multiple surgeries.</p><p>Data have consistently suggested that the use of anti-TNF agents throughout pregnancy may lower the risk of a disease flare [<a href="#rid125">125,127</a>]. In a population-based study including 5293 pregnancies exposed to anti-TNF agents from conception, use of anti-TNF therapy beyond 24 weeks was associated with lower risk of a maternal IBD flare compared with stopping anti-TNF therapy, after adjusting for factors such as IBD type and glucocorticoid use (35.8 versus 39 percent; adjusted risk ratio [aRR] 0.93, 95% CI 0.86-0.99) [<a href="#rid125">125</a>]. In addition, continuing anti-TNF agents beyond 24 weeks was not associated with increased risk of adverse pregnancy outcomes (ie, stillbirth, low birth weight, preterm birth). </p><p>The use of anti-TNF agents (alone or in combination with thiopurines) during pregnancy does not appear to increase the risk of severe infection for the child [<a href="#rid122">122,125</a>]. In a study with mean follow-up of four years that included 841 children born to mothers with IBD, the rate of severe infection was similar in children exposed to anti-TNF agents in utero compared with unexposed children (1.6 versus 2.8 percent per person-year; HR 1.2, 95% CI 0.8-1.8) [<a href="#rid122">122</a>].</p><p>Use of anti-TNF therapy during pregnancy has not been associated with an increased risk of adverse pregnancy outcomes, and continuing anti-TNF therapy beyond 24 weeks may lower the risk of preterm birth [<a href="#rid125">125,128-132</a>]. In a study including 5293 pregnancies exposed to anti-TNF agents from conception, use of anti-TNF therapy beyond 24 weeks was associated with lower risk of preterm birth compared with stopping anti-TNF therapy (7.6 versus 8.9 percent; aRR 0.82, 95% CI 0.68-0.99) [<a href="#rid125">125</a>]. In an analysis of data from a prospective cohort (Pregnancy in IBD and Neonatal Outcomes Registry [PIANO]) including 1490 pregnant patients (ie, 242 patients exposed to <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, 642 patients exposed to biologics, 227 patients exposed to combination therapy, and 379 patients unexposed), use of biologic, thiopurine, or combination therapy was not associated with increased risk for congenital malformations, spontaneous abortion, preterm birth, low birth weight, or infections at one year [<a href="#rid132">132</a>]. Patients with ulcerative colitis tended to have higher rates of disease activity compared with patients with Crohn disease. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p class="headingAnchor" id="H2205519119"><span class="h3">Infliximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a> is compatible with use during conception in male and female patients and throughout pregnancy [<a href="#rid121">121,126</a>]. Rates of live births, miscarriages, and therapeutic terminations do not appear to be significantly different in patients exposed to infliximab during pregnancy compared with the general population [<a href="#rid129">129,133-135</a>].</p><p><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a> should be continued throughout pregnancy to avoid flares. Discontinuation of therapy can lead to increased disease activity and increased adverse outcomes to the child [<a href="#rid125">125,127</a>]. While there is no formal need for adjustment, generally the last dose during pregnancy is given at least two weeks prior to anticipated delivery. Infliximab is considered compatible with breastfeeding as it is excreted in trace amounts in human milk and is poorly absorbed orally, thus reducing the potential for systemic adverse effects [<a href="#rid6">6,136</a>].</p><p><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a> crosses the placenta [<a href="#rid137">137</a>]. The exact timing is unclear, but in general, maternal antibodies are actively transported across the placenta by the neonatal Fc receptor (FcRn) beginning in the early to mid-second trimester, with the highest fetal concentration in the third trimester near term. High levels of infliximab have been detected in the cord blood of newborns [<a href="#rid137">137,138</a>], and this raises concern about an increased risk of infection and a suboptimal response to vaccinations in the newborn [<a href="#rid139">139</a>]. However, in a cohort study including 179 pregnant patients with IBD, infants born to mothers on biologic therapy did not have lower rates of adequate serologic response to <em>Haemophilus influenza B</em> (HiB) or tetanus toxin following vaccination compared with infants unexposed to biologic therapy (HiB group: 71 versus 50 percent, and tetanus toxoid group: 80 versus 75 percent) [<a href="#rid140">140</a>]. In addition, the median cord blood concentrations of infliximab were similar in infants with an adequate serologic response to the vaccines compared with infants without an adequate response.</p><p>Live vaccines should not be given to infants exposed to <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a>, or <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">natalizumab</a>, as newborns may have detectable serum levels of drug for up to nine months [<a href="#rid126">126,137,141</a>]. All other vaccinations can be given on schedule. (See  <a class="medical medical_review" href="/z/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview", section on 'Routine schedule'</a>.)</p><p class="headingAnchor" id="H1859773535"><span class="h3">Adalimumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">Adalimumab</a> is considered compatible with use during conception and throughout pregnancy [<a href="#rid126">126</a>]. In observational studies, the incidence of congenital malformations, spontaneous abortion, stillbirth, and preterm delivery was not increased in pregnant patients exposed to adalimumab [<a href="#rid137">137,138,142</a>]. Adalimumab actively crosses the placenta as well [<a href="#rid137">137</a>].</p><p>Limited evidence suggests that <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> is compatible with breastfeeding. While it can be detected in breast milk, levels are low and it has not been demonstrated to adversely affect the nursing infant [<a href="#rid143">143</a>].</p><p class="headingAnchor" id="H2625650736"><span class="h3">Certolizumab</span><span class="headingEndMark"> — </span>Certolizumab is a PEGylated Fab fragment of a humanized anti-TNF-alpha monoclonal antibody. Unlike other anti-TNF agents, which are actively transferred across the placenta in the third trimester, there is minimal placental transfer of certolizumab to the infant during pregnancy as it does not have an Fc component to bind to the FcRn on the placenta [<a href="#rid137">137</a>].</p><p>Certolizumab can therefore be used through conception and continued throughout pregnancy until delivery. Although there are limited data, <a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">certolizumab pegol</a> may also be compatible with breastfeeding as it is minimally excreted into breast milk [<a href="#rid121">121</a>]. There is no need to adjust vaccine schedules in infants exposed to certolizumab in utero.</p><p class="headingAnchor" id="H2893062229"><span class="h3">Other anti-TNF agents</span><span class="headingEndMark"> — </span>We typically continue <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a> in patients with ulcerative colitis who are pregnant or breastfeeding. (See  <a class="medical medical_review" href="/z/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults", section on 'Tumor necrosis factor inhibitors'</a>.) </p><p class="headingAnchor" id="H2532287678"><span class="h2">Other biologic agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">Vedolizumab</a> – We typically continue vedolizumab in pregnant patients to avoid disease flares. Limited data on vedolizumab use during pregnancy suggested that vedolizumab was not associated with an increased risk of miscarriage, stillbirth, or congenital anomalies [<a href="#rid144">144,145</a>]. In an observational, case-control study including 73 patients with IBD (79 pregnancies), miscarriage rates were not significantly different for patients given vedolizumab compared with patients given anti-TNF agents or a control group who were not exposed to biologics or immunomodulators (16 versus 13 and 10 percent, respectively) [<a href="#rid144">144</a>]. Stillbirth rates were not significantly different for patients treated with vedolizumab compared with anti-TNF agents or with an unexposed control group. In addition, data from 25 pregnancies in patients with IBD found no increase in congenital anomalies [<a href="#rid145">145</a>].</p><p></p><p class="bulletIndent1">For patients who are breastfeeding, we also continue <a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">vedolizumab</a> therapy. Vedolizumab is detectable at very low levels in breastmilk, which is similar to other biologic therapies [<a href="#rid146">146</a>]. (See <a class="local">'Anti-tumor necrosis factor agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">Ustekinumab</a> – There are limited safety data in Crohn disease, but safety registries in psoriasis report a 1.7 percent rate of fetal malformations, similar to what would be expected in the general population [<a href="#rid147">147</a>]. There are limited human data on lactation safety, but again, it is the author's practice to continue use during breastfeeding in the healthy term infant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">Risankizumab</a> – We typically continue risankizumab in pregnant patients to reduce the risk of a disease flare. Limited studies did not show an increased risk of adverse pregnancy outcomes or infant adverse effects with use of risankizumab during pregnancy or lactation [<a href="#rid148">148</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="143211" href="/z/d/drug information/143211.html" rel="external">Mirikizumab</a><strong> – </strong>We typically continue mirikizumab in pregnant patients based on its presumed minimal transfer across the placenta in the first trimester (similar to other monoclonal antibodies) and to avoid disease flares [<a href="#rid149">149</a>]. However, safety data on mirikizumab in patients with IBD during pregnancy are lacking.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">Natalizumab</a> – There are limited safety data on the use of natalizumab during pregnancy and lactation. The risk of congenital malformations was not increased in 164 pregnancies in patients with Crohn disease or multiple sclerosis on natalizumab during the first trimester [<a href="#rid150">150</a>].</p><p></p><p class="headingAnchor" id="H2822293545"><span class="h2">Small molecules</span><span class="headingEndMark"> — </span>Small molecules may cross the placenta early in pregnancy during the period of organogenesis. Thus, we avoid using small molecules in pregnant patients for this reason, in addition to an increased risk of congenital anomalies in animal studies.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">Tofacitinib</a> – We avoid use of tofacitinib in pregnant patients (particularly in the first trimester) and in breastfeeding mothers. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">Upadacitinib</a> – We avoid the use of upadacitinib in pregnant patients. Upadacitinib crosses the placenta in the first trimester, and animal data show teratogenicity at doses equal to and less than the daily human dose [<a href="#rid151">151</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sphingosine 1-phosphate (S1P) receptor modulators</strong> – We avoid the use of S1P receptor modulators (<a class="drug drug_general" data-topicid="127521" href="/z/d/drug information/127521.html" rel="external">ozanimod</a> and <a class="drug drug_general" data-topicid="143076" href="/z/d/drug information/143076.html" rel="external">etrasimod</a>) in pregnant patients and breastfeeding mothers.</p><p></p><p class="headingAnchor" id="H840594013"><span class="h2">Antidiarrheal drugs</span><span class="headingEndMark"> — </span>Antidiarrheal drugs should be avoided, especially early in pregnancy. Antidiarrheals should only be used for severe diarrhea that cannot be controlled with dietary manipulation and bulking agents (eg, kaolin/pectin, <a class="drug drug_general" data-topicid="9834" href="/z/d/drug information/9834.html" rel="external">psyllium</a>).</p><p>Diphenoxylate with <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> and <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">loperamide</a> are not teratogenic in animal studies but there are no controlled studies in humans. Case reports have reported fetal malformations in infants exposed to diphenoxylate with atropine during the first trimester, but it is unclear if this was causal [<a href="#rid152">152,153</a>].</p><p><a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">Loperamide</a> is compatible with nursing [<a href="#rid80">80</a>]. However, there are no data for diphenoxylate. <a class="drug drug_general" data-topicid="9370" href="/z/d/drug information/9370.html" rel="external">Diphenoxylate-atropine</a> should therefore be used only in short, infrequent courses, at low doses while breastfeeding an older infant.</p><p class="headingAnchor" id="H2390764677"><span class="h2">Anticoagulants</span><span class="headingEndMark"> — </span>Pregnancy and the puerperium, as well as a diagnosis of IBD, are well-established risk factors for deep vein thrombosis (DVT) and pulmonary embolism (PE), which are collectively referred to as venous thromboembolic disease (VTE). Patients should receive VTE prophylaxis during any hospitalization and after cesarean delivery [<a href="#rid1">1</a>]. Prevention of VTE and the use of anticoagulants in pregnant patients are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1347.html" rel="external">"Venous thromboembolism in pregnancy: Prevention"</a> and  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p class="headingAnchor" id="H771982581"><span class="h1">SURGERY</span><span class="headingEndMark"> — </span>Complications associated with IBD that warrant surgery in a pregnant patient include acute refractory colitis, perforation, abscesses, severe hemorrhage, and obstruction [<a href="#rid6">6</a>]. There are limited data pertaining to the risk of surgery in pregnant patients with IBD [<a href="#rid154">154,155</a>]. Surgery has been associated with preterm labor and spontaneous abortions, possibly related to inadvertent uterine manipulation, but complications are rare [<a href="#rid6">6,156,157</a>]. When possible, medical treatment should be intensified prior to considering surgery [<a href="#rid158">158</a>]. (See  <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults", section on 'Acute complications'</a> and  <a class="medical medical_review" href="/z/d/html/86198.html" rel="external">"Surgical management of Crohn disease"</a>.)</p><p>Nonurgent surgery that cannot wait until delivery is ideally performed in the second trimester. The timing of nonobstetric surgery for pregnant patients is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121990.html" rel="external">"Nonobstetric surgery in pregnant patients: Patient counseling, surgical considerations, and obstetric management", section on 'Timing of surgery'</a>.)</p><p class="headingAnchor" id="H115650664"><span class="h1">MODE OF DELIVERY</span><span class="headingEndMark"> — </span>Patients with active perineal disease or rectal involvement with Crohn disease should undergo cesarean delivery in order to avoid perineal trauma from vaginal birth that can trigger or worsen existing perineal disease [<a href="#rid126">126,159</a>]. The mode of delivery in all other patients with inflammatory bowel disease should be dictated by obstetric necessity. In patients with an ileoanal anastomosis or J pouch, many advocate planned cesarean delivery as well, though data suggest no long-term worsening of pouch function [<a href="#rid159">159</a>].</p><p>Vaginal delivery can be attempted in patients with a colostomy, ileostomy, or continent ileostomy and has not been associated with an increased risk of ostomy complications [<a href="#rid6">6,160</a>]. (See  <a class="medical medical_review" href="/z/d/html/1384.html" rel="external">"Ileostomy or colostomy care and complications"</a>.)</p><p class="headingAnchor" id="H3307793717"><span class="h1">POSTPARTUM CARE</span><span class="headingEndMark"> — </span>Some studies have reported an increased risk of postpartum flares [<a href="#rid29">29,161,162</a>]. Risk factors for disease flares may include hormonal fluctuations, discontinuing IBD medications during lactation, and resuming tobacco use [<a href="#rid162">162</a>]. For patients with a clear pregnancy plan who continue medications during lactation, follow-up should occur within six months following delivery or sooner if symptoms develop or worsen prior to the visit.</p><p>Normal physiologic changes and routine maternal care in the postpartum period are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6711.html" rel="external">"Overview of the postpartum period: Normal physiology and routine maternal care"</a>.)</p><p class="headingAnchor" id="H3705963349"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109937.html" rel="external">"Society guideline links: Ulcerative colitis in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/109856.html" rel="external">"Society guideline links: Crohn disease in adults"</a>.)</p><p class="headingAnchor" id="H1636144556"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/1994.html" rel="external">"Patient education: Inflammatory bowel disease and pregnancy (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3606059585"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – IBD can affect patients in their childbearing years and therefore has implications for fertility, pregnancy, and nursing. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">Patients with quiescent IBD do not have decreased fertility compared with the general population. However, fertility in patients with IBD may be affected by active inflammation, medications, and prior surgery. (See <a class="local">'Fertility'</a> above.)</p><p></p><p class="bulletIndent1">During pregnancy, patients with ulcerative colitis have more disease activity than patients with Crohn disease. Pregnant patients with IBD are at an increased risk for worse obstetric and pregnancy-related outcomes compared with the general population, even with disease in remission. (See <a class="local">'Pregnancy and lactation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preconception counseling </strong>– The course of IBD during pregnancy is determined in part by the activity of the disease at conception. Patients in remission at the time of conception are likely to remain in remission during pregnancy. In contrast, up to 70 percent of patients with active disease at conception are likely to have continued or worsening symptoms during pregnancy. (See <a class="local">'Disease control'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation during pregnancy </strong>– Endoscopy should be performed during pregnancy only if there is a strong indication or if the information is critical for making treatment decisions. An unsedated flexible sigmoidoscopy is considered low risk. Magnetic resonance enterography is the preferred diagnostic modality in pregnant patients with IBD in the absence of institutional expertise with ultrasound for IBD. (See <a class="local">'Evaluating disease activity during pregnancy and lactation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medication use </strong>– The choice of anti-inflammatory and immunosuppressive medications during pregnancy and lactation should be based upon their relative safety and indications as well as the risk of relapse of IBD if the medications are discontinued. (See <a class="local">'Medications during pregnancy and lactation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mode of delivery </strong>– Patients with perineal disease or rectal involvement with Crohn disease should undergo a cesarean delivery. The mode of delivery in all other patients with IBD should be dictated by obstetric necessity. (See <a class="local">'Mode of delivery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery in pregnant patients </strong>– Complications associated with IBD that warrant surgery in a pregnant patient include acute refractory colitis, perforation, abscesses, severe hemorrhage, and obstruction. Although data are limited, surgery is associated with premature labor or spontaneous abortion, possibly related to inadvertent uterine manipulation. (See <a class="local">'Surgery'</a> above.)</p><p></p><p class="headingAnchor" id="H35709241"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Paul Rutgeerts, MD (deceased), who contributed as a section editor for UpToDate in Gastroenterology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology 2019; 156:1508.</a></li><li><a class="nounderline abstract_t">Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology 1990; 99:987.</a></li><li><a class="nounderline abstract_t">Hudson M, Flett G, Sinclair TS, et al. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet 1997; 58:229.</a></li><li><a class="nounderline abstract_t">Woolfson K, Cohen Z, McLeod RS. Crohn's disease and pregnancy. Dis Colon Rectum 1990; 33:869.</a></li><li><a class="nounderline abstract_t">Tavernier N, Fumery M, Peyrin-Biroulet L, et al. Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38:847.</a></li><li><a class="nounderline abstract_t">Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis 2010; 4:63.</a></li><li><a class="nounderline abstract_t">Birnie GG, McLeod TI, Watkinson G. Incidence of sulphasalazine-induced male infertility. Gut 1981; 22:452.</a></li><li><a class="nounderline abstract_t">O'Moráin C, Smethurst P, Doré CJ, Levi AJ. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 1984; 25:1078.</a></li><li><a class="nounderline abstract_t">Toovey S, Hudson E, Hendry WF, Levi AJ. Sulphasalazine and male infertility: reversibility and possible mechanism. Gut 1981; 22:445.</a></li><li><a class="nounderline abstract_t">Ley D, Jones J, Parrish J, et al. Methotrexate Reduces DNA Integrity in Sperm From Men With Inflammatory Bowel Disease. Gastroenterology 2018; 154:2064.</a></li><li><a class="nounderline abstract_t">Grosen A, Bungum M, Christensen LA, et al. Semen Quality and Sperm DNA Integrity in Patients With Severe Active Inflammatory Bowel Disease and Effects of Tumour Necrosis Factor-alpha Inhibitors. J Crohns Colitis 2019; 13:564.</a></li><li><a class="nounderline abstract_t">Narendranathan M, Sandler RS, Suchindran CM, Savitz DA. Male infertility in inflammatory bowel disease. J Clin Gastroenterol 1989; 11:403.</a></li><li><a class="nounderline abstract_t">Ørding Olsen K, Juul S, Berndtsson I, et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002; 122:15.</a></li><li><a class="nounderline abstract_t">Waljee A, Waljee J, Morris AM, Higgins PD. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006; 55:1575.</a></li><li><a class="nounderline abstract_t">Nørgård BM, Larsen PV, Fedder J, et al. Live birth and adverse birth outcomes in women with ulcerative colitis and Crohn's disease receiving assisted reproduction: a 20-year nationwide cohort study. Gut 2016; 65:767.</a></li><li><a class="nounderline abstract_t">Laharie D, Debeugny S, Peeters M, et al. Inflammatory bowel disease in spouses and their offspring. Gastroenterology 2001; 120:816.</a></li><li><a class="nounderline abstract_t">Roth MP, Petersen GM, McElree C, et al. Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews. Gastroenterology 1989; 96:1016.</a></li><li><a class="nounderline abstract_t">Yang H, McElree C, Roth MP, et al. Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut 1993; 34:517.</a></li><li><a class="nounderline abstract_t">Satsangi J, Grootscholten C, Holt H, Jewell DP. Clinical patterns of familial inflammatory bowel disease. Gut 1996; 38:738.</a></li><li><a class="nounderline abstract_t">Jølving LR, Nielsen J, Beck-Nielsen SS, et al. The Association Between Maternal Chronic Inflammatory Bowel Disease and Long-term Health Outcomes in Children-A Nationwide Cohort Study. Inflamm Bowel Dis 2017; 23:1440.</a></li><li><a class="nounderline abstract_t">Bayless TM, Tokayer AZ, Polito JM 2nd, et al. Crohn's disease: concordance for site and clinical type in affected family members--potential hereditary influences. Gastroenterology 1996; 111:573.</a></li><li><a class="nounderline abstract_t">Colombel JF, Grandbastien B, Gower-Rousseau C, et al. Clinical characteristics of Crohn's disease in 72 families. Gastroenterology 1996; 111:604.</a></li><li><a class="nounderline abstract_t">Polito JM 2nd, Childs B, Mellits ED, et al. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996; 111:580.</a></li><li><a class="nounderline abstract_t">Peeters M, Nevens H, Baert F, et al. Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 1996; 111:597.</a></li><li><a class="nounderline abstract_t">Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009; 7:972.</a></li><li><a class="nounderline abstract_t">Annese V, Andreoli A, Astegiano M, et al. Clinical features in familial cases of Crohn's disease and ulcerative colitis in Italy: a GISC study. Italian Study Group for the Disease of Colon and Rectum. Am J Gastroenterol 2001; 96:2939.</a></li><li><a class="nounderline abstract_t">Grandbastien B, Peeters M, Franchimont D, et al. Anticipation in familial Crohn's disease. Gut 1998; 42:170.</a></li><li><a class="nounderline abstract_t">Abhyankar A, Ham M, Moss AC. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38:460.</a></li><li><a class="nounderline abstract_t">Pedersen N, Bortoli A, Duricova D, et al. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther 2013; 38:501.</a></li><li><a class="nounderline abstract_t">Nørgård B, Hundborg HH, Jacobsen BA, et al. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol 2007; 102:1947.</a></li><li><a class="nounderline abstract_t">Shaffer JL, Kershaw A, Berrisford MH. Sulphasalazine-induced infertility reversed on transfer to 5-aminosalicylic acid. Lancet 1984; 1:1240.</a></li><li><a class="nounderline abstract_t">Wu FC, Aitken RJ, Ferguson A. Inflammatory bowel disease and male infertility: effects of sulfasalazine and 5-aminosalicylic acid on sperm-fertilizing capacity and reactive oxygen species generation. Fertil Steril 1989; 52:842.</a></li><li><a class="nounderline abstract_t">Friedman S, Larsen MD, Magnussen B, et al. Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring-A nationwide cohort study. Reprod Toxicol 2017; 73:196.</a></li><li><a class="nounderline abstract_t">Saxena AK, Dhungel S, Bhattacharya S, et al. Effect of chronic low dose of methotrexate on cellular proliferation during spermatogenesis in rats. Arch Androl 2004; 50:33.</a></li><li><a class="nounderline abstract_t">Winter RW, Larsen MD, Magnussen B, et al. Birth outcomes after preconception paternal exposure to methotrexate: A nationwide cohort study. Reprod Toxicol 2017; 74:219.</a></li><li><a class="nounderline abstract_t">Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19:15.</a></li><li><a class="nounderline abstract_t">Meserve J, Luo J, Zhu W, et al. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases. Gastroenterology 2021; 161:107.</a></li><li><a class="nounderline abstract_t">Gubatan J, Barber GE, Nielsen OH, et al. Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2023; 21:2222.</a></li><li><a class="nounderline abstract_t">Xu L, Han S, Liu Y, et al. The influence of immunosuppressants on the fertility of males who undergo renal transplantation and on the immune function of their offspring. Transpl Immunol 2009; 22:28.</a></li><li><a class="nounderline abstract_t">Bengtson MB, Aamodt G, Mahadevan U, Vatn MH. Inadequate Gestational Weight Gain, the Hidden Link Between Maternal IBD and Adverse Pregnancy Outcomes: Results from the Norwegian Mother and Child Cohort Study. Inflamm Bowel Dis 2017; 23:1225.</a></li><li><a class="nounderline abstract_t">Mullin GE. Micronutrients and inflammatory bowel disease. Nutr Clin Pract 2012; 27:136.</a></li><li><a class="nounderline abstract_t">Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007; 56:830.</a></li><li><a class="nounderline abstract_t">Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007; 133:1106.</a></li><li><a class="nounderline abstract_t">Nguyen GC, Boudreau H, Harris ML, Maxwell CV. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2009; 7:329.</a></li><li><a class="nounderline abstract_t">Kane S, Kisiel J, Shih L, Hanauer S. HLA disparity determines disease activity through pregnancy in women with inflammatory bowel disease. Am J Gastroenterol 2004; 99:1523.</a></li><li><a class="nounderline abstract_t">Nielsen OH, Andreasson B, Bondesen S, Jarnum S. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983; 18:735.</a></li><li><a class="nounderline abstract_t">Hanan IM, Kirsner JB. Inflammatory bowel disease in the pregnant woman. Clin Perinatol 1985; 12:669.</a></li><li><a class="nounderline abstract_t">Rogers RG, Katz VL. Course of Crohn's disease during pregnancy and its effect on pregnancy outcome: a retrospective review. Am J Perinatol 1995; 12:262.</a></li><li class="breakAll">Korelitz BI. Pregnancy. In: Seminars in Colon and Rectal Surgery, Peppercorn MA (Ed), WB Saunders, 1993. p.48.</li><li><a class="nounderline abstract_t">Castiglione F, Pignata S, Morace F, et al. Effect of pregnancy on the clinical course of a cohort of women with inflammatory bowel disease. Ital J Gastroenterol 1996; 28:199.</a></li><li><a class="nounderline abstract_t">Riis L, Vind I, Politi P, et al. Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol 2006; 101:1539.</a></li><li><a class="nounderline abstract_t">Bröms G, Granath F, Linder M, et al. Complications from inflammatory bowel disease during pregnancy and delivery. Clin Gastroenterol Hepatol 2012; 10:1246.</a></li><li><a class="nounderline abstract_t">Bortoli A, Pedersen N, Duricova D, et al. Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther 2011; 34:724.</a></li><li><a class="nounderline abstract_t">Bröms G, Granath F, Linder M, et al. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis 2014; 20:1091.</a></li><li><a class="nounderline abstract_t">Getahun D, Fassett MJ, Longstreth GF, et al. Association between maternal inflammatory bowel disease and adverse perinatal outcomes. J Perinatol 2014; 34:435.</a></li><li><a class="nounderline abstract_t">Nørgård B, Fonager K, Sørensen HT, Olsen J. Birth outcomes of women with ulcerative colitis: a nationwide Danish cohort study. Am J Gastroenterol 2000; 95:3165.</a></li><li><a class="nounderline abstract_t">Stephansson O, Larsson H, Pedersen L, et al. Crohn's disease is a risk factor for preterm birth. Clin Gastroenterol Hepatol 2010; 8:509.</a></li><li><a class="nounderline abstract_t">Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol 2008; 103:1203.</a></li><li><a class="nounderline abstract_t">Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol 1984; 6:211.</a></li><li><a class="nounderline abstract_t">Khosla R, Willoughby CP, Jewell DP. Crohn's disease and pregnancy. Gut 1984; 25:52.</a></li><li><a class="nounderline abstract_t">Mayberry JF, Weterman IT. European survey of fertility and pregnancy in women with Crohn's disease: a case control study by European collaborative group. Gut 1986; 27:821.</a></li><li><a class="nounderline abstract_t">Fedorkow DM, Persaud D, Nimrod CA. Inflammatory bowel disease: a controlled study of late pregnancy outcome. Am J Obstet Gynecol 1989; 160:998.</a></li><li><a class="nounderline abstract_t">Kane S, Lemieux N. The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am J Gastroenterol 2005; 100:102.</a></li><li><a class="nounderline abstract_t">Shmidt E, Dubinsky MC. Inflammatory Bowel Disease and Pregnancy. Am J Gastroenterol 2022; 117:60.</a></li><li><a class="nounderline abstract_t">Julsgaard M, Hvas CL, Gearry RB, et al. Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2017; 23:1240.</a></li><li><a class="nounderline abstract_t">Kim ES, Tarassishin L, Eisele C, et al. Longitudinal Changes in Fecal Calprotectin Levels Among Pregnant Women With and Without Inflammatory Bowel Disease and Their Babies. Gastroenterology 2021; 160:1118.</a></li><li><a class="nounderline abstract_t">Tandon P, Lee EY, Maxwell C, et al. Fecal Calprotectin May Predict Adverse Pregnancy-Related Outcomes in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021; 66:1639.</a></li><li><a class="nounderline abstract_t">Kammerlander H, Nielsen J, Kjeldsen J, et al. Fecal Calprotectin During Pregnancy in Women With Moderate-Severe Inflammatory Bowel Disease. Inflamm Bowel Dis 2018; 24:839.</a></li><li><a class="nounderline abstract_t">Cappell MS, Colon VJ, Sidhom OA. A study at 10 medical centers of the safety and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy with follow-up of fetal outcome and with comparison to control groups. Dig Dis Sci 1996; 41:2353.</a></li><li><a class="nounderline abstract_t">Homan WP, Thorbjarnarson B. Crohn disease and pregnancy. Arch Surg 1976; 111:545.</a></li><li><a class="nounderline abstract_t">Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 2007; 188:1447.</a></li><li><a class="nounderline abstract_t">De Voogd F, Joshi H, Van Wassenaer E, et al. Intestinal Ultrasound to Evaluate Treatment Response During Pregnancy in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2022; 28:1045.</a></li><li><a class="nounderline abstract_t">Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 2017; 377:613.</a></li><li><a class="nounderline abstract_t">Prakash P, Dua A, Blumenfeld Y, et al. Longitudinal Trends in Pregnancy Outcomes Among Women With Inflammatory Bowel Disease in the Era of Biologics: A 20-Year Nationwide Analysis. Inflamm Bowel Dis 2023.</a></li><li><a class="nounderline abstract_t">Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol 1998; 105:322.</a></li><li><a class="nounderline abstract_t">Caro-Patón T, Carvajal A, Martin de Diego I, et al. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol 1997; 44:179.</a></li><li><a class="nounderline abstract_t">Beard CM, Noller KL, O'Fallon WM, et al. Cancer after exposure to metronidazole. Mayo Clin Proc 1988; 63:147.</a></li><li><a class="nounderline abstract_t">Falagas ME, Walker AM, Jick H, et al. Late incidence of cancer after metronidazole use: a matched metronidazole user/nonuser study. Clin Infect Dis 1998; 26:384.</a></li><li><a class="nounderline abstract_t">Koss CA, Baras DC, Lane SD, et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob Agents Chemother 2012; 56:4800.</a></li><li><a class="nounderline abstract_t">American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.</a></li><li><a class="nounderline abstract_t">Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother 1998; 42:1336.</a></li><li><a class="nounderline abstract_t">Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case-control teratologic study. Eur J Obstet Gynecol Reprod Biol 2001; 97:188.</a></li><li><a class="nounderline abstract_t">Jodlowski TZ, Oehler R, Kam LW, Melnychuk I. Emerging therapies in the treatment of Clostridium difficile-associated disease. Ann Pharmacother 2006; 40:2164.</a></li><li><a class="nounderline abstract_t">Reid G, Kumar H, Khan AI, et al. The case in favour of probiotics before, during and after pregnancy: insights from the first 1,500 days. Benef Microbes 2016; 7:353.</a></li><li><a class="nounderline abstract_t">Mogadam M, Dobbins WO 3rd, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981; 80:72.</a></li><li><a class="nounderline abstract_t">Järnerot G, Into-Malmberg MB, Esbjörner E. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Scand J Gastroenterol 1981; 16:693.</a></li><li><a class="nounderline abstract_t">Järnerot G, Andersen S, Esbjörner E, et al. Albumin reserve for binding of bilirubin in maternal and cord serum under treatment with sulphasalazine. Scand J Gastroenterol 1981; 16:1049.</a></li><li><a class="nounderline abstract_t">Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology 1993; 105:1057.</a></li><li><a class="nounderline abstract_t">Bell CM, Habal FM. Safety of topical 5-aminosalicylic acid in pregnancy. Am J Gastroenterol 1997; 92:2201.</a></li><li><a class="nounderline abstract_t">Trallori G, d'Albasio G, Bardazzi G, et al. 5-Aminosalicylic acid in pregnancy: clinical report. Ital J Gastroenterol 1994; 26:75.</a></li><li><a class="nounderline abstract_t">Diav-Citrin O, Park YH, Veerasuntharam G, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998; 114:23.</a></li><li class="breakAll">US Food and Drug Administration. Asacol (mesalamine) delayed release tablets -- Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER), May 2010. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm215476.htm (Accessed on December 14, 2011).</li><li><a class="nounderline abstract_t">Berlin CM Jr, Yaffe SJ. Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk. Dev Pharmacol Ther 1980; 1:31.</a></li><li><a class="nounderline abstract_t">Nelis GF. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet 1989; 1:383.</a></li><li><a class="nounderline abstract_t">Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62:385.</a></li><li><a class="nounderline abstract_t">Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011; 183:796.</a></li><li><a class="nounderline abstract_t">Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978; 202:436.</a></li><li><a class="nounderline abstract_t">Yang K. Placental 11 beta-hydroxysteroid dehydrogenase: barrier to maternal glucocorticoids. Rev Reprod 1997; 2:129.</a></li><li><a class="nounderline abstract_t">Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. JAMA 1995; 273:413.</a></li><li><a class="nounderline abstract_t">Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992; 166:1318.</a></li><li><a class="nounderline abstract_t">Gur C, Diav-Citrin O, Shechtman S, et al. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 2004; 18:93.</a></li><li><a class="nounderline abstract_t">Greenberger PA, Odeh YK, Frederiksen MC, Atkinson AJ Jr. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther 1993; 53:324.</a></li><li><a class="nounderline abstract_t">Alstead EM, Ritchie JK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990; 99:443.</a></li><li><a class="nounderline abstract_t">Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124:9.</a></li><li><a class="nounderline abstract_t">van Dieren JM, Kuipers EJ, Samsom JN, et al. Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis 2006; 12:311.</a></li><li><a class="nounderline abstract_t">Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol 2006; 101:1048.</a></li><li><a class="nounderline abstract_t">Ierardi E, Principi M, Francavilla R, et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther 2001; 15:371.</a></li><li><a class="nounderline abstract_t">Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:129.</a></li><li><a class="nounderline abstract_t">Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 2008; 14:7.</a></li><li><a class="nounderline abstract_t">Nørgård B, Pedersen L, Christensen LA, Sørensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102:1406.</a></li><li><a class="nounderline abstract_t">Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011; 60:198.</a></li><li><a class="nounderline abstract_t">Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008; 28:1209.</a></li><li><a class="nounderline abstract_t">Sau A, Clarke S, Bass J, et al. Azathioprine and breastfeeding: is it safe? BJOG 2007; 114:498.</a></li><li><a class="nounderline abstract_t">Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001; 71:1051.</a></li><li><a class="nounderline abstract_t">Petri M. Immunosuppressive drug use in pregnancy. Autoimmunity 2003; 36:51.</a></li><li><a class="nounderline abstract_t">Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody. Hum Exp Toxicol 2000; 19:226.</a></li><li><a class="nounderline abstract_t">Østensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8:209.</a></li><li><a class="nounderline abstract_t">Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003; 30:241.</a></li><li><a class="nounderline abstract_t">Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk. Am J Obstet Gynecol 1972; 112:978.</a></li><li><a class="nounderline abstract_t">O'Donnell S, O'Morain C. Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment Pharmacol Ther 2008; 27:885.</a></li><li><a class="nounderline abstract_t">Mahadevan U, Cucchiara S, Hyams JS, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011; 106:214.</a></li><li><a class="nounderline abstract_t">Chaparro M, Verreth A, Lobaton T, et al. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. Am J Gastroenterol 2018; 113:396.</a></li><li><a class="nounderline abstract_t">Matro R, Martin CF, Wolf D, et al. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. Gastroenterology 2018; 155:696.</a></li><li><a class="nounderline abstract_t">Nielsen OH, Gubatan JM, Juhl CB, et al. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2022; 20:74.</a></li><li><a class="nounderline abstract_t">Meyer A, Neumann A, Drouin J, et al. Benefits and Risks Associated With Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease : A Nationwide Emulation Trial. Ann Intern Med 2022; 175:1374.</a></li><li><a class="nounderline abstract_t">Nguyen GC, Seow CH, Maxwell C, et al. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology 2016; 150:734.</a></li><li><a class="nounderline abstract_t">Luu M, Benzenine E, Doret M, et al. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION). Am J Gastroenterol 2018; 113:1669.</a></li><li><a class="nounderline abstract_t">Nielsen OH, Loftus EV Jr, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med 2013; 11:174.</a></li><li><a class="nounderline abstract_t">Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011; 17:1846.</a></li><li><a class="nounderline abstract_t">Seirafi M, de Vroey B, Amiot A, et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther 2014; 40:363.</a></li><li><a class="nounderline abstract_t">O'Byrne LJ, Alqatari SG, Maher GM, et al. Fetal and maternal outcomes after maternal biologic use during conception and pregnancy: A systematic review and meta-analysis. BJOG 2022; 129:1236.</a></li><li><a class="nounderline abstract_t">Mahadevan U, Long MD, Kane SV, et al. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology 2021; 160:1131.</a></li><li><a class="nounderline abstract_t">Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99:2385.</a></li><li><a class="nounderline abstract_t">Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4:621.</a></li><li><a class="nounderline abstract_t">Lichtenstein GR, Feagan BG, Mahadevan U, et al. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol 2018; 113:1678.</a></li><li><a class="nounderline abstract_t">Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 2011; 5:555.</a></li><li><a class="nounderline abstract_t">Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11:286.</a></li><li><a class="nounderline abstract_t">Zelinkova Z, van der Ent C, Bruin KF, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013; 11:318.</a></li><li><a class="nounderline abstract_t">Cheent K, Nolan J, Shariq S, et al. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010; 4:603.</a></li><li><a class="nounderline abstract_t">Beaulieu DB, Ananthakrishnan AN, Martin C, et al. Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clin Gastroenterol Hepatol 2018; 16:99.</a></li><li><a class="nounderline abstract_t">Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology 2016; 151:110.</a></li><li><a class="nounderline abstract_t">Chambers CD, Johnson DL, Xu R, et al. Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study. PLoS One 2019; 14:e0223603.</a></li><li><a class="nounderline abstract_t">Ben-Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 2010; 8:475.</a></li><li><a class="nounderline abstract_t">Moens A, van der Woude CJ, Julsgaard M, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther 2020; 51:129.</a></li><li><a class="nounderline abstract_t">Mahadevan U, Dubinsky M, Vermeire S, et al. Vedolizumab exposure in pregnancy: Outcomes from clinical studies in ulcerative colitis and Crohn's disease. Abstract. Am J Gastroenterol 2015; 80:S1.</a></li><li><a class="nounderline abstract_t">Lahat A, Shitrit AB, Naftali T, et al. Vedolizumab Levels in Breast Milk of Nursing Mothers With Inflammatory Bowel Disease. J Crohns Colitis 2018; 12:120.</a></li><li><a class="nounderline abstract_t">Levy RA, de Jesús GR, de Jesús NR, Klumb EM. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev 2016; 15:955.</a></li><li class="breakAll">Risankizumab. United States Prescribing Information. Revised 09/2022. US Food &amp; Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761105s016lbl.pdf (Accessed on November 04, 2022).</li><li><a class="nounderline abstract_t">D'Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2023; 388:2444.</a></li><li><a class="nounderline abstract_t">Nazareth M, Cristiano L, Kooijmans M. Natalizumab use during pregnancy. Am J Gastroenterol 2008; 104.</a></li><li class="breakAll">Upadacitinib. United States Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211675s010lbl.pdf (Accessed on November 16, 2022).</li><li><a class="nounderline abstract_t">Lewis JH, Weingold AB. The use of gastrointestinal drugs during pregnancy and lactation. Am J Gastroenterol 1985; 80:912.</a></li><li class="breakAll">Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 8th ed, Lippincott Williams &amp; Wilkins, Philadelphia, PA 2008.</li><li><a class="nounderline abstract_t">Boulton R, Hamilton M, Lewis A, et al. Fulminant ulcerative colitis in pregnancy. Am J Gastroenterol 1994; 89:931.</a></li><li><a class="nounderline abstract_t">Watson WJ, Gaines TE. Third-trimester colectomy for severe ulcerative colitis. A case report. J Reprod Med 1987; 32:869.</a></li><li><a class="nounderline abstract_t">Anderson JB, Turner GM, Williamson RC. Fulminant ulcerative colitis in late pregnancy and the puerperium. J R Soc Med 1987; 80:492.</a></li><li><a class="nounderline abstract_t">Dozois EJ, Wolff BG, Tremaine WJ, et al. Maternal and fetal outcome after colectomy for fulminant ulcerative colitis during pregnancy: case series and literature review. Dis Colon Rectum 2006; 49:64.</a></li><li><a class="nounderline abstract_t">Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm Bowel Dis 2008; 14:1736.</a></li><li><a class="nounderline abstract_t">Foulon A, Dupas JL, Sabbagh C, et al. Defining the Most Appropriate Delivery Mode in Women with Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis 2017; 23:712.</a></li><li><a class="nounderline abstract_t">Van Horn C, Barrett P. Pregnancy, delivery, and postpartum experiences of fifty-four women with ostomies. J Wound Ostomy Continence Nurs 1997; 24:151.</a></li><li><a class="nounderline abstract_t">Tirath A, Kane SV. Disease Flares in the Postpartum Period: Vigilance Is Key. Inflamm Bowel Dis 2022; 28:484.</a></li><li><a class="nounderline abstract_t">Bennett A, Mamunes A, Kim M, et al. The Importance of Monitoring the Postpartum Period in Moderate to Severe Crohn's Disease. Inflamm Bowel Dis 2022; 28:409.</a></li></ol></div><div id="topicVersionRevision">Topic 4083 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30658060" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2394353" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Increased risk of preterm birth for women with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9252260" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Fertility and pregnancy in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2209277" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Crohn's disease and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24004045" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Systematic review: fertility in non-surgically treated inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21122490" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6114898" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence of sulphasalazine-induced male infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6148293" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reversible male infertility due to sulphasalazine: studies in man and rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6114897" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Sulphasalazine and male infertility: reversibility and possible mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29481778" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Methotrexate Reduces DNA Integrity in Sperm From Men With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30500868" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Semen Quality and Sperm DNA Integrity in Patients With Severe Active Inflammatory Bowel Disease and Effects of Tumour Necrosis Factor-alpha Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2760429" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Male infertility in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781275" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16772310" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26921349" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Live birth and adverse birth outcomes in women with ulcerative colitis and Crohn's disease receiving assisted reproduction: a 20-year nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11231934" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Inflammatory bowel disease in spouses and their offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2925048" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8491401" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8707121" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical patterns of familial inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28719543" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The Association Between Maternal Chronic Inflammatory Bowel Disease and Long-term Health Outcomes in Children-A Nationwide Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8780559" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Crohn's disease: concordance for site and clinical type in affected family members--potential hereditary influences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8780563" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical characteristics of Crohn's disease in 72 families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8780560" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Crohn's disease: influence of age at diagnosis on site and clinical type of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8780562" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19422935" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Genetic risk profiling and prediction of disease course in Crohn's disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11693330" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical features in familial cases of Crohn's disease and ulcerative colitis in Italy: a GISC study. Italian Study Group for the Disease of Colon and Rectum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9536939" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Anticipation in familial Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23855477" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23855425" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17573787" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6144952" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sulphasalazine-induced infertility reversed on transfer to 5-aminosalicylic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2572460" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Inflammatory bowel disease and male infertility: effects of sulfasalazine and 5-aminosalicylic acid on sperm-fertilizing capacity and reactive oxygen species generation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28844800" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring-A nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14660169" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of chronic low dose of methotrexate on cellular proliferation during spermatogenesis in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29080667" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Birth outcomes after preconception paternal exposure to methotrexate: A nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22434610" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33744307" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35870769" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19818850" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The influence of immunosuppressants on the fertility of males who undergo renal transplantation and on the immune function of their offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28452861" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Inadequate Gestational Weight Gain, the Hidden Link Between Maternal IBD and Adverse Pregnancy Outcomes: Results from the Norwegian Mother and Child Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22223669" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Micronutrients and inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17185356" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A meta-analysis on the influence of inflammatory bowel disease on pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17764676" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19027089" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15307871" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : HLA disparity determines disease activity through pregnancy in women with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6669937" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pregnancy in ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2865025" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Inflammatory bowel disease in the pregnant woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7575831" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Course of Crohn's disease during pregnancy and its effect on pregnancy outcome: a retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7575831" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Course of Crohn's disease during pregnancy and its effect on pregnancy outcome: a retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8842834" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effect of pregnancy on the clinical course of a cohort of women with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16863558" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22922307" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Complications from inflammatory bowel disease during pregnancy and delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21815900" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24810137" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24651735" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Association between maternal inflammatory bowel disease and adverse perinatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095336" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Birth outcomes of women with ulcerative colitis: a nationwide Danish cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20202483" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Crohn's disease is a risk factor for preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422816" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6144706" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6140209" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Crohn's disease and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3732892" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : European survey of fertility and pregnancy in women with Crohn's disease: a case control study by European collaborative group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2712128" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Inflammatory bowel disease: a controlled study of late pregnancy outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15654788" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36194035" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Inflammatory Bowel Disease and Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28498159" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33307026" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Longitudinal Changes in Fecal Calprotectin Levels Among Pregnant Women With and Without Inflammatory Bowel Disease and Their Babies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32533542" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fecal Calprotectin May Predict Adverse Pregnancy-Related Outcomes in Patients with Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29506137" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Fecal Calprotectin During Pregnancy in Women With Moderate-Severe Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9011442" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A study at 10 medical centers of the safety and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy with follow-up of fetal outcome and with comparison to control groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1267600" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Crohn disease and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17515363" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : ACR guidance document for safe MR practices: 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34525186" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Intestinal Ultrasound to Evaluate Treatment Response During Pregnancy in Patients With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28657417" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37857421" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Longitudinal Trends in Pregnancy Outcomes Among Women With Inflammatory Bowel Disease in the Era of Biologics: A 20-Year Nationwide Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9532994" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A population based case-control teratologic study of oral metronidazole treatment during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9278206" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Is metronidazole teratogenic? A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3339906" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cancer after exposure to metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9502459" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Late incidence of cancer after metronidazole use: a matched metronidazole user/nonuser study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22751543" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Investigation of metronidazole use during pregnancy and adverse birth outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533352" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Transfer of drugs and other chemicals into human milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9624471" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11451547" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: a population-based case-control teratologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17119105" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Emerging therapies in the treatment of Clostridium difficile-associated disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26839074" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The case in favour of probiotics before, during and after pregnancy: insights from the first 1,500 days.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6108894" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6119765" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6121372" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Albumin reserve for binding of bilirubin in maternal and cord serum under treatment with sulphasalazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8405849" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9399752" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Safety of topical 5-aminosalicylic acid in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8032081" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : 5-Aminosalicylic acid in pregnancy: clinical report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9428214" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The safety of mesalamine in human pregnancy: a prospective controlled cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9428214" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The safety of mesalamine in human pregnancy: a prospective controlled cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6108198" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2563532" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Diarrhoea due to 5-aminosalicylic acid in breast milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11091360" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21482652" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Corticosteroid use during pregnancy and risk of orofacial clefts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/705336" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Prenatal exposure to prednisone in humans and animals retards intrauterine growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9414475" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Placental 11 beta-hydroxysteroid dehydrogenase: barrier to maternal glucocorticoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7823388" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1595785" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15013068" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8453851" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Pharmacokinetics of prednisolone transfer to breast milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2365192" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Safety of azathioprine in pregnancy in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12512024" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16633053" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16573777" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11207512" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17206694" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17879277" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17437503" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115547" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18761704" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Azathioprine treatment during lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17261122" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Azathioprine and breastfeeding: is it safe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11374400" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12765471" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Immunosuppressive drug use in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10918512" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16712713" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Anti-inflammatory and immunosuppressive drugs and reproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12563675" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5042796" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Secretion of methotrexate into human milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18284649" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21157441" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29460920" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Long-Term Safety of In Utero Exposure to Anti-TNFαDrugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29857090" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32931960" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36162111" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Benefits and Risks Associated With Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease : A Nationwide Emulation Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26688268" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29961771" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Continuous Anti-TNFαUse Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23902720" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Safety of TNF-αinhibitors during IBD pregnancy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21830263" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24980270" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35014759" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Fetal and maternal outcomes after maternal biologic use during conception and pregnancy: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33227283" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15571587" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16678077" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30022113" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22115374" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23200982" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23103819" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21122568" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28870657" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27063728" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31626646" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20005982" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Adalimumab level in breast milk of a nursing mother.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31692017" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Vedolizumab exposure in pregnancy: Outcomes from clinical studies in ulcerative colitis and Crohn's disease. Abstract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28961712" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Vedolizumab Levels in Breast Milk of Nursing Mothers With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27490204" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27490204" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37379135" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Natalizumab use during pregnancy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Natalizumab use during pregnancy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2864852" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : The use of gastrointestinal drugs during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2864852" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : The use of gastrointestinal drugs during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8198108" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Fulminant ulcerative colitis in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3430496" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Third-trimester colectomy for severe ulcerative colitis. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3656334" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Fulminant ulcerative colitis in late pregnancy and the puerperium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16320006" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Maternal and fetal outcome after colectomy for fulminant ulcerative colitis during pregnancy: case series and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626967" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Management of the pregnant IBD patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28426452" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Defining the Most Appropriate Delivery Mode in Women with Inflammatory Bowel Disease: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9224023" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Pregnancy, delivery, and postpartum experiences of fifty-four women with ostomies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33999156" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Disease Flares in the Postpartum Period: Vigilance Is Key.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33999196" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : The Importance of Monitoring the Postpartum Period in Moderate to Severe Crohn's Disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
